IDStewardship

  • Home
  • Articles
  • LEARN ANTIBIOTICS
  • Study Guide
  • Resources
  • Q&A
  • #ASPchat
  • Contributors
  • About

Tocilizumab (Actemra)

Tocilizumab photo

This webpage is focused on tocilizumab for COVID-19. This is an evolving topic and information may be quickly be rendered inaccurate. Caution is advised. 

KEY POINTS

  • Tocilizumab (Actemra) is a humanized monoclonal antibody targeting IL-6R and it inhibits binding of IL-6 to its receptors while not blocking the signaling of other IL-6 family cytokines
  • Tocilizumab holds FDA approvals for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis
  • Tocilizuamab had an FDA Emergency Use Authorization (EUA) for tocilizumab for COVID-19 released on 24 June 2021. It was subsequently FDA-approved for COVID-19 in December 2022.
  • Tocilizumab carries a boxed warning for serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections
  • As of late 2023, the debate is between when to use baricitinib or tocilizumab in patients with COVID-19 who have progressive respiratory disease requiring intervention. Refer to the NIH COVID-19 guideline for more on this topic.
  • Tocilizumab is expensive

RESOURCES/ LITERATURE

  • Tocilizumab (Actemra) Package Insert
  • COVID-19 NIH Guidelines (a go-to resource for all COVID-19 therapies)
  • Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
  • Interventional & Observational Studies / Reports:
    • Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia – COVACTA in NEJM
      • Editorial commentary: Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
    • Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – REMAP-CAP in NEJM
    • Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – LANCET
    • Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial – PREPRINT
    • Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
      • In patients with severe or critical covid-19, tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.
    • REMAP-CAP Website
      • REMAP-CAP Pre-Print Sudy
      • UK Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)
        • Provides recommended inclusion/ exclusion criteria based upon REMAP-CAP
    • Impact of Interleukin-6 receptor blockade with Tocilizumab on Cardiac Injury in Patients with COVID-19: a retrospective cohort study
    • Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report (pre-print)
    • Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
      • In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival.
    • Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
      • Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide.
    • Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: Randomized Clinical Trial
      • The administration of tocilizumab in patients with COVID-19 pneumonia and a Pao2/Fio2 ratio between 200 and 300 mm Hg did not reduce the risk of clinical worsening; further blinded, placebo-controlled randomized clinical trials are needed to confirm the results and to evaluate possible applications of tocilizumab in different stages of the disease.
    • Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
      • Tocilizumab may reduce the need for mechanical and noninvasive ventilation or death by day 14 but not mortality by day 28; further studies are necessary to confirm these preliminary results.
    • Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
      • These findings suggest that among critically ill patients with COVID-19, early treatment with tocilizumab may reduce mortality, although the findings may be susceptible to unmeasured confounding, and further research from randomized clinical trials is needed.
    • Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies
      • Results showed that mortality was 12% lower for COVID-19 patients treated with tocilizumab compared to COVID-19 patients who were not treated with tocilizumab. The number needed to treat was 11, suggesting that for every 11 (severe) COVID-19 patients treated with tocilizumab 1 death is prevented. These results require confirmation by randomized controlled trials.
        • These conclusions should be interpreted with caution
    • Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
    • Tocilizumab for severe COVID‐19 in solid organ transplant recipients: a matched case‐control study
      • In this matched control cohort study, tocilizumab appeared to be safe but was not associated with decreased 90‐day mortality.
    • Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
      • In this observational study, patients with COVID-19 requiring ICU support who received tocilizumab had reduced mortality. Results of ongoing randomised controlled trials are awaited.
    • Tocilizumab for treatment of mechanically ventilated patients with COVID-19
    • Early combination of Tocilizumab and Corticosteroids: An upgrade in anti-inflammatory therapy for severe COVID
    • The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases
    • Tocilizumab in patients with severe COVID-19: a retrospective cohort study
    • Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
    • Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes
      • No comparator group, but includes a cohort of 239 patients
    • Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
      • Describes outcomes for 62 hospitalized patients with COVID-19 that received tocilizumab, finding it had a positive impact if used early during COVID-19 pneumonia with severe respiratory syndrome in terms of increased survival and favorable clinical course.
    • Tocilizumab treatment in COVID‐19: a single center experience
      • Reports on 15 patients who received tocilizumab
  • Commentaries:
    • It is time to determine Tocilizumab place in COVID-19 – CID
    • Tocilizumab in COVID-19: Give it time!
    • Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia
      • Newly released randomized trials suggest a potential role for tocilizumab in COVID-19 but do not show clear evidence of efficacy, in contrast to observational studies. Their findings do not support the routine use of tocilizumab for COVID-19 in most settings.
    • Tocilizumab versus the covid19 tempest: all’s well that ends well or much ado about nothing?
    • Efficacy of Tocilizumab for treatment of severe COVID-19 Pneumonia: more evidence is needed
    • Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment?
    • COVID-19: Clean up on IL-6
    • To Toci or Not to Toci for COVID-19: Is That Still the Question?
    • Is a “Cytokine Storm” Relevant to COVID-19?
    • The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
      • Reviews the potential benefit of toccilizumab for COVID-19
  • Media Releases:
    • Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
    • Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia
      • COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality
      • COVACTA pre-print is here
  • Other:
    • Cost-effectiveness of tocilizumab in severe COVID-19: to see or not to see – CID
    • Fixed dosing of tocilizumab in ICU admitted COVID-19 patients is a superior choice compared to bodyweight based dosing; an observational population pharmacokinetic and pharmacodynamic study – Pre-Print
      The first 12 months of COVID-19: a timeline of immunological insights
    • Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition) states:
      • For patients with extensive and bilateral lung disease and severely ill patients with elevated IL-6 levels, treatment with tocilizumab may be attempted
      • The initial dose should be 4-8mg/kg, with the recommended dosage being 400mg
      • Dilute with 0.9% saline to 100ml and infuse over the course of more than 1 hour
      • Repeat once after 12 hours (same dosage) if the response to the first dose was poor, mximum two cumulative doses
      • Single maximum dose is 800mg
      • Pay attention to allergic reactions
      • Prohibited in patients with active infections such as tuberculosis

RECOMMENDED TO YOU


 

Free Antibiotic Cheat Sheet

Study Guide

  • Pharmacotherapy Study Guide
  • Acyclovir (Zovirax)
  • Albendazole (Albenza)
  • Amikacin
  • Aminoglycosides
  • Amphotericin B (Fungizone, Abelcet, Ambisome)
  • Amoxicillin (Amoxil)
  • Amoxicillin-Clavulanic Acid (Augmentin)
  • Ampicillin
  • Ampicillin-sulbactam (Unasyn)
  • Anidulafungin (Eraxis)
  • Artesunate
  • Atovaquone (Mepron)
  • Azithromycin (Zithromax, Zmax)
  • Aztreonam (Azactam, Cayston)
  • Aztreonam-avibactam (Emblaveo)
  • Bacitracin
  • Baloxavir marboxyl (Xofluza)
  • Bamlanivimab
  • Baricitinib (Olumiant)
  • Bebtelovimab
  • Bezlotoxumab (Zinplava)
  • Brincidofovir (Tembexa)
  • Cantharidin (Ycanth)
  • Casirivimab and Imdevimab (REGEN-COV)
  • Caspofungin (Cancidas)
  • Cefazolin (Ancef)
  • Cefepime (Maxipime)
  • Cefepime-enmetazobactam (Exblifep)
  • Cefepime-Taniborbactam
  • Cefiderocol (Fetroja)
  • Ceftaroline (Teflaro)
  • Ceftazidime (Fortaz, Tazicef)
  • Ceftazidime-avibactam (Avycaz)
  • Ceftobiprole medocaril (Zevtera)
  • Ceftolozane-Tazobactam (Zerbaxa)
  • Ceftriaxone (Rocephin)
  • Cefoxitin (Mefoxin)
  • Cephalexin (Keflex)
  • Cidofovir (Vistide)
  • Ciprofloxacin (Cipro)
  • Clarithromycin (Biaxin)
  • Clindamycin (Cleocin)
  • Colistin (colistimethate)
  • Cycloserine (Seromycin)
  • Dalbavancin (Dalvance)
  • Daptomycin (Cubicin)
  • Delafloxacin (Baxdela)
  • Dicloxacillin
  • Doripenem (Doribax)
  • Doxycycline (Doryx)
  • Elbasvir/ grazoprevir (Zepatier)
  • Eravacycline (Xerava)
  • Ertapenem (Invanz)
  • Erythromycin
  • Famciclovir (Famvir)
  • Fecal Microbiota Spores, Live-brpk (Vowst, SER-109)
  • Fidaxomicin (Dificid)
  • Fluconazole (Diflucan)
  • Flucytosine (Ancobon)
  • Foscarnet (Foscavir)
  • Fosfomycin (Monurol)
  • Ganciclovir (Cytovene)
  • Gentamicin (Garamycin)
  • Gepotidacin (Blujepa)
  • Glecaprevir/ Pibrentasvir (Mavyret)
  • Ibrexafungerp (Brexafemme)
  • Imipenem-cilastatin (Primaxin)
  • Imipenem-cilastatin-relebactam (Recarbrio)
  • Isavuconazole (Cresemba)
  • Itraconazole (Sporanox)
  • Ivermectin (Stromectol)
  • Ledipasvir/sofosbuvir (Harvoni)
  • Lefamulin (Xenleta)
  • Letermovir (Prevymis)
  • Levofloxacin (Levaquin)
  • Linezolid (Zyvox)
  • Maribavir (Livtencity)
  • Meropenem (Merrem)
  • Meropenem-vaborbactam (Vabomere)
  • Metronidazole (Flagyl)
  • Methenamine (Hiprex, Urex)
  • Micafungin (Mycamine)
  • Minocycline (Minocin)
  • Molnupiravir (Lagevrio)
  • Moxifloxacin (Avelox)
  • Nafcillin
  • Nitrofurantoin (Macrobid, Macrodantin)
  • Omadacycline (Nuzyra)
  • Oritavancin (Orbactiv, Kimyrsa)
  • Oseltamivir (Tamiflu)
  • Oteseconazole (Vivjoa)
  • Oxacillin
  • Nirmatrelvir/ ritonavir (Paxlovid)
  • Penicillin
  • Penicillin Skin Test
  • Phenazopyridine (AZO)
  • Piperacillin-tazobactam (Zosyn)
  • Pivmecillinam (Pivya)
  • Plazomicin (Zemdri)
  • Polymyxin B
  • Posaconazole (Noxafil)
  • Quinupristin-dalfopristin (Synercid)
  • Remdesivir (Veklury)
  • Rezafungin (Rezzayo)
  • Ribavirin
  • Rifabutin (Mycobutin)
  • Rifampin (Rifadin)
  • Secnidazole (Solosec)
  • Sofosbuvir/ velpatasvir/ voxilaprevir (Vosevi)
  • Sulopenem etzadroxil and Probenecid (Orlynvah)
  • Sotrovimab (Xevudy)
  • Sulbactam-durlobactam (Xacduro)
  • Sulfadiazine
  • Sulfamethoxazole-Trimethoprim (Bactrim)
  • Tecovirimat (TPOXX)
  • Tedizolid (Sivextro)
  • Telavancin (Vibativ)
  • Tigecycline (Tygacil)
  • Tobramycin
  • Tocilizumab (Actemra)
  • Valacyclovir (Valtrex)
  • Valganciclovir (Valcyte)
  • Vancomycin
  • Voriconazole (VFend)
  • Zidovudine (Retrovir)
  • Zoster vaccine recombinant, adjuvanted (Shingrix)

Recent

  • Pharmacy Student Study Strategies To Maximizing Learning In 2025 And Beyond
  • 5 Things To Know About Interpreting MRSA Nares Swab Results
  • Five Tidbits From The Largest International Meeting Of Clinical Microbiologists & Infectious Diseases Specialists In 2025
  • Five Things For Pharmacists To Know About Measles in 2025
  • 5 Things You Need To Know About The Learn Antibiotics Book Of Games

Search

Copyright 2016-2020 By Charlie Rose, LLC © · IDStewardship.com · Copyright · Privacy Policy · Terms · Contact